APLP2 with a KD of about 200 nM to about 800 nM, as measured by surface plasmon resonance, or equivalent assay.

12. The bispecific antigen-binding molecule of claim **1**, wherein the first antigen-binding domain binds human APLP2 with a KD of about 800 nM to about 1 μM, as measured by surface plasmon resonance, or equivalent assay.

13. The bispecific antigen-binding molecule of claim **1**, wherein the second antigen-binding domain binds human HER2 with a KD of less than 10 nM, as measured by surface plasmon resonance, or equivalent assay.

14. The bispecific antigen-binding molecule of claim **1**, wherein the second antigen-binding domain binds human HER2 with a KD of about 3 nM to about 5 nM, as measured by surface plasmon resonance, or equivalent assay.

15. The bispecific antigen-binding molecule of claim **1**, wherein the first antigen-binding domain binds human with a KD of about 100 nM to about 1 μM, and the second antigen-binding domain binds human with a KD of less than 10 nM, wherein KD is measured by surface plasmon resonance, or equivalent assay.

16. The bispecific antigen-binding molecule of claim **1**, wherein the first antigen binding domain is derived from the antibody or antigen-binding fragment comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 2, and the second antigen-binding domain is derived from the antibody or antigen-binding fragment comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 1.

17. The antibody or antigen-binding fragment of claim **1**, wherein the antibody or antigen-binding fragment thereof competes for binding to human APLP2 with a reference antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 2.

18. The bispecific antigen-binding molecule of claim **1**, wherein the reference antibody comprises an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs:26/10, 34/10, and 42/10.

19. The bispecific antigen-binding molecule of claim **1**, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on human APLP2 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 2.

20. The bispecific antigen-binding molecule of claim **1**, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on human APLP2 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 26/10, 34/10, and 42/10.

21. The bispecific antigen-binding molecule of claim **1**, wherein the antigen-binding molecule inhibits tumor growth in immunocompromised mice bearing human breast cancer xenografts.

22. The bispecific antigen-binding molecule of claim **1**, that is a bispecific antibody or bispecific antigen-binding fragment thereof.

23. The bispecific antigen-binding molecule of claim **1**, wherein the second antigen-binding domain that specifically binds human HER2 comprises the heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) from a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NOs: 2 and 18,

the second antigen-binding domain that specifically binds human HER2 comprises the heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) from a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NOs: 2 and 18; and the light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) from a light chain variable region (LCVR) comprising an amino acid sequence consisting of SEQ ID NO: 10.

24. The bispecific antigen-binding molecule of claim **1**, wherein the second antigen-binding domain that specifically binds human HER2 comprises three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3), wherein A2-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:4 and 20; A2-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:6 and 22; A2-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:8 and 24; A2-LCDR1 comprises an amino acid sequence of SEQ ID NO:12; A2-LCDR2 comprises an amino acid sequence of SEQ ID NO:14; and A2-LCDR3 comprises an amino acid sequence of SEQ ID NO:16.

25. The bispecific antigen-binding molecule of claim **1**, wherein the second antigen-binding domain that specifically binds human HER2 comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair of: SEQ ID NOs: 18/10.

26. The bispecific antigen-binding molecule of claim **1**, wherein the first antigen-binding domain that specifically binds human APLP2 comprises heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) from a heavy chain variable region (HCVR) comprising an amino acid sequence as set forth in Table 2 and light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) from a light chain variable region (LCVR) comprising an amino acid sequence as set forth in Table 2.

27. The bispecific antigen-binding molecule of claim **1**, wherein the first antigen-binding domain that specifically binds human APLP2 comprises heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) from a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NOs: 26, 34, and 42, and light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) from a light chain variable region (LCVR) comprising an amino acid sequence of SEQ ID NO: 10.

28. The bispecific antigen-binding molecule of claim **1**, wherein the first antigen-binding domain that specifically binds human APLP2 comprises three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3),

wherein A1-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 28, 36, and 44; A1-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 38, and 46; A1-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 32, 40 and 48; A1-LCDR1 comprises an amino acid sequence of SEQ ID NO:12; A1-LCDR2